The approval of the ART25.12 New Drug Application will enable Artelo to initiate a Phase 1 trial of the drug for chemotherapy-induced peripheral neuropathy.
FDA Approves Altero Biosciences’ Investigational New Drug Application for Treatment of Chemotherapy-Induced Peripheral Neuropathy
Leave a comment
